TEMPEST THERAPEUTICS, INC.

Profile

Company Names

TEMPEST THERAPEUTICS, INC.
OVASCIENCE, INC.

Addresses

2000 SIERRA POINT PARKWAY, SUITE 400, BRISBANE, CA 94005

2000 SIERRA POINT PARKWAY, SUITE 400, BRISBANE, CA 94005

7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO, CA 94080

215 FIRST STREET, SUITE 240, CAMBRIDGE, MA 02142

800 BOYLSTON STREET, SUITE 1555, BOSTON, MA 02199

Phone Numbers

415-798-8589
(415) 798-8589
617-902-0682
617-351-2590

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

2011

State Incorporated:

DELAWARE

Total Amount Raised:

$98,230,655.00

Number of Funding Rounds:

6
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
6
2026-05-29 
$4,056,552.00 
$4,056,552.00 
$0.00 
Equity 
5
2026-03-20 
$1,999,539.00 
$1,999,539.00 
$0.00 
Equity 
4
2022-04-26 
$15,000,000.00 
$15,000,000.00 
$0.00 
Equity 
3
2013-03-18 
$34,999,920.00 
$34,999,920.00 
$0.00 
Equity 
2
2012-06-21 
$4,936,547.00 
$4,936,547.00 
$0.00 
Equity 
1
2012-03-29 
$37,238,097.00 
$37,238,097.00 
$0.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
RICHARD 
 
ALDRICH 
DIRECTOR
MATTHEW 
 
ANGEL 
EXECUTIVE OFFICER, DIRECTOR
CHRISTOPHER 
A. 
BLECK 
EXECUTIVE OFFICER
STEPHEN 
 
BRADY 
DIRECTOR
STEPHEN 
R. 
BRADY 
EXECUTIVE OFFICER, DIRECTOR
JEFF 
 
CAPELLO 
DIRECTOR
SCOTT 
 
CHAPPEL 
EXECUTIVE OFFICER
THOMAS 
W. 
DUBENSKY 
EXECUTIVE OFFICER, DIRECTOR
MICHAEL 
 
FLANAGAN 
EXECUTIVE OFFICER
ALISON 
 
LAWTON 
EXECUTIVE OFFICER
NICHOLAS 
 
MAESTAS 
EXECUTIVE OFFICER
GEOFFREY 
 
NICHOL 
DIRECTOR
CHRISTINE 
 
PELLIZZARI 
DIRECTOR
MICHAEL 
 
RAAB 
DIRECTOR
WILLIAM 
DRAKE 
RICHEY 
DIRECTOR
RONIT 
 
SIMANTOV 
DIRECTOR
HARALD 
 
STOCK 
DIRECTOR
JONATHAN 
 
TILLY 
DIRECTOR
JUSTIN 
 
TROJANOWSKI 
EXECUTIVE OFFICER
JOHN 
DAVID 
YEE 
DIRECTOR
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2026-05-29 
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
NO REVENUES 
Equity 
2026-03-20 
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
NO REVENUES 
Equity 
2022-04-26 
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2013-03-18 
D/A
BIOTECHNOLOGY 
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835] 
DECLINE TO DISCLOSE 
Equity 
2012-06-21 
D/A
BIOTECHNOLOGY 
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835] 
DECLINE TO DISCLOSE 
Equity 
2012-06-21 
D/A
BIOTECHNOLOGY 
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835] 
DECLINE TO DISCLOSE 
Equity 
2012-06-21 
D
BIOTECHNOLOGY 
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835] 
DECLINE TO DISCLOSE 
Equity 
2012-06-21 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2012-03-29 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
NONE
NONE
LEERINK SWANN LLC
NONE
NONE
LADENBURG THALMAN + CO. INC.
505
NONE
NONE
OPPENHEIMER + CO., INC.
249
NONE
NONE
ROTH CAPITAL PARTNERS, LLC
NONE
NONE
WEDBUSH SECURITIES INC.
877
NONE
NONE
LEERINK SWANN LLC
NONE
NONE
LIVINGSTON SECURITIES, LLC
NONE
NONE
OPPENHEIMER + CO., INC.
249
NONE
NONE
NEWBRIDGE SECURITIES CORPORATION
NONE
NONE
ROTH CAPITAL PARTNERS, LLC